Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trisequens Forte
- Development stage
- Phase 3
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trisequens Forte is a continuous sequential hormone replacement therapy (HRT) product containing estradiol and norethisterone acetate. It is used to treat symptoms of estrogen deficiency associated with menopause, such as hot flushes, night sweats, and to prevent osteoporosis in postmenopausal women. The medication delivers higher doses of hormones compared to regular Trisequens, with a 28-day cycle consisting of three different tablet types: 12 days of estrogen-only therapy (yellow tablets), followed by 10 days of combined estrogen/progestagen therapy (white tablets), and 6 days of lower-dose estrogen therapy (red tablets).
- Brand names
- Trisequens Forte
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on Trisequens Forte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trisequens Forte.